BioCentury | Feb 12, 2020
Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

A trio of Weill Cornell and Sloan Kettering researchers have launched Volastra with $12 million in seed funding to develop therapies targeting chromosomal instability -- a driver of cancer metastasis. Polaris Partners led the seed...
BioCentury | Jan 11, 2020
Targets & Mechanisms

Colitis-associated somatic mutations yield new colorectal cancer target

Kyoto University team identifies colitis-associated somatic mutations that are lost in colitis-associated cancer to reveal a new colorectal cancer target. A Japanese team has identified novel colorectal cancer targets by contrasting somatic mutations in cancerous...
BC Extra | Nov 15, 2019
Financial News

Despite flurry of deals, follow-ons well short of 2018’s total

Four companies led by Reata raised over $600 million in follow-ons ahead of Thursday’s trading session, but even with the bolus of funding this year’s follow-ons lag last year’s pace. A fifth company, Halozyme Therapeutics...
BC Extra | Nov 13, 2019
Clinical News

Bardoxolone data set Reata up to advance second compound toward registration

Weeks after regaining rights to cardiorenal compounds from AbbVie, Reata has reported its second pivotal trial success of the quarter, paving the way for global marketing applications for its two most advanced compounds as it...
BC Extra | Oct 14, 2019
Clinical News

Reata’s pivotal data in Friedreich ataxia point to submissions

Days after regaining worldwide rights to omaveloxolone, Reata announced plans to submit regulatory applications in the U.S. and other territories for the compound in Friedreich ataxia based on newly released pivotal trial data. Reata Pharmaceuticals...
BC Extra | Oct 10, 2019
Company News

On eve of pivotal data, Reata pays AbbVie $330M to regain cardiorenal candidates

With AbbVie having turned away from cardiovascular and renal indications, Reata reacquired rights to bardoxolone and second-generation NRF2 activators from its long-standing partner for $330 million in cash ahead of upcoming pivotal readouts for two...
BC Innovations | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

Interest in kidney diseases is mounting among investors, biotechs and pharmas at a rate reminiscent of the liver disease explosion almost a decade ago. The momentum is driven by improvements at both ends of the...
BC Extra | Aug 27, 2019
Clinical News

DMD data to inform Santhera's choice under vamorolone option deal

Santhera and ReveraGen revealed Tuesday that glucocorticoid vamorolone showed improvement in timed function tests, the primary outcome for clinical efficacy, in a Phase IIa extension study in boys ages 4-7 with Duchenne muscular dystrophy. Santhera...
BC Innovations | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

Grace Science is targeting the root of a recently discovered genetic disorder for not just the ultra-rare condition but also for common diseases including cancer. Grace Science LLC’s origins stem from the diagnosis of co-founder...
BC Innovations | Aug 8, 2019
Translation in Brief

A cool menthol switch for gene expression

ETH Zurich researchers have created a synthetic gene circuit activated by topical menthol to switch on gene expression and protein production in engineered cells. In a July Nature Medicine paper , the team used the circuit...
Items per page:
1 - 10 of 261